Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPTRAUMA: Intermediate vs Standard Dose Enoxaparin in Severe Trauma
NCT07506473Not yet recruiting
- Sponsor
- CHU Grenoble Alpes
- Start
- Apr 2026
- Primary completion
- May 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Composite of symptomatic deep vein thrombosis (DVT), proximal DVT, pulmonary embolism (PE) at 14 days. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07506473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07506473.